Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results

Core Insights - Dianthus Therapeutics is advancing its investigational monoclonal antibody DNTH103 for severe autoimmune diseases, with key clinical trials ongoing and results expected in the coming years [1][2][3] Clinical Development - The Phase 2 MaGic trial for DNTH103 in generalized Myasthenia Gravis (gMG) is on track to report top-line results in the second half of 2025 [1][4] - The Phase 3 CAPTIVATE trial for DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is ongoing, with an interim responder analysis anticipated in the second half of 2026 [1][5] - The Phase 2 MoMeNtum trial for DNTH103 in Multifocal Motor Neuropathy (MMN) is also ongoing, with top-line results expected in the second half of 2026 [1][6] Financial Position - As of December 31, 2024, the company reported $357.0 million in cash, cash equivalents, and investments, providing a financial runway into the second half of 2027 [1][14] - Research and development expenses for 2024 were$83.1 million, a significant increase from $32.8 million in 2023, primarily due to higher clinical costs and increased headcount [14] - General and administrative expenses for 2024 totaled$25.0 million, up from $18.2 million in 2023, driven by increased headcount and professional services costs [14] Leadership Updates - John C. King was appointed as Chief Commercial Officer, bringing over 25 years of experience in biotechnology, while Sujay Kango joined the Board of Directors with over 26 years in the pharmaceutical and biotechnology sector [7]